Fate Therapeutics
FATE
149 hedge funds and large institutions have $1.15B invested in Fate Therapeutics in 2019 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 56 increasing their positions, 42 reducing their positions, and 14 closing their positions.
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
33% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 42
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
10% more funds holding
Funds holding: 136 → 149 (+13)
1.1% more ownership
Funds ownership: 96.88% → 97.98% (+1.1%)
11% less capital invested
Capital invested by funds: $1.28B → $1.15B (-$137M)
12% less call options, than puts
Call options by funds: $3.97M | Put options by funds: $4.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GH
Grosvenor Holdings
Chicago,
Illinois
|
+$43.8M |
| 2 |
Millennium Management
New York
|
+$25.5M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$16.4M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$15.3M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$11.9M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$10.2M |
| 4 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$6.39M |
| 5 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$4.92M |
FATE Hedge Fund Activity: Q3 2019 in Review
149 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2019, worth a combined $1.15B — down 11% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FATE positions and 14 closed out — a net gain of 13 holders — while 56 added to existing stakes and 42 trimmed.
The largest buyer was Grosvenor Holdings, opening a new position worth an estimated $43.8M. The largest seller was PFM Health Sciences, cutting an estimated $12.8M.
- 149 institutional investors held Fate Therapeutics (FATE) as of Q3 2019, up from 136 in Q2 2019.
- Funds reported $1.15B of Fate Therapeutics stock for Q3 2019, down 11% quarter-over-quarter.
- 27 funds opened new Fate Therapeutics positions in Q3 2019 and 14 closed out, a net change of +13 holders.
- The largest Fate Therapeutics buyer in Q3 2019 was Grosvenor Holdings, an estimated $43.8M added.
- The largest Fate Therapeutics seller in Q3 2019 was PFM Health Sciences, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2019.